Select a State

Global health R&D delivers for Massachusetts

US government investment in global health R&D has delivered

$731.1 million
to Massachusetts research institutions
8,400+ new jobs
for Massachusetts

Neglected diseases in Massachusetts

Chikungunya cases
234
Dengue cases
33
HIV diagnoses
6241
Malaria cases
388
Tuberculosis cases
1916
West Nile cases
88
Zika cases
129

Massachusetts's top USG-funded global health R&D institutions

Harvard University (including School of Public Health, Public Health AIDS Initiative, and Harvard Medical School)
$135 million
Massachusetts General Hospital (including CAMtech and Center for Integration of Medicine & Innovative Technology)
$93.4 million
Beth Israel Deaconess Medical Center
$89.8 million
Brigham and Women's Hospital
$82.3 million
University of Massachusetts Medical School
$80.4 million
Broad Institute
$44.1 million
Children's Hospital Boston (including Children's Hospital Corporation and Immune Disease Institute)
$51.8 million
Tufts University (including Tufts Medical Center)
$34.4 million
Dana-Farber Cancer Institute
$32 million
Boston University (including Boston University Medical Campus and Center for Global Health and Development)
$24.3 million
Boston Medical Center
$13.1 million
Massachusetts Institute of Technology
$9.7 million
Brandeis University
$6.5 million
Northeastern University
$6 million
Whitehead Institute for Biomedical Research
$5.6 million
Fenway Health
$4.4 million
The Forsyth Institute
$4.1 million
Harvard Pilgrim Health Care, Inc.
$3.9 million
University of Massachusetts Amherst
$2.9 million
Novartis Vaccines Institute for Global Health
$2.2 million
The Home for Little Wanderers including Boston Children's Services
$1.7 million
Worcester Polytechnic Institute
$1.2 million
Boston Biomedical Research Institute
$731 thousand
Boston College
$532 thousand
Clark University
$394 thousand
Howard M. Shapiro
$331 thousand
University of Massachusetts Boston
$300 thousand

Massachusetts industry in global health R&D

AbbVie
Location(s):
Worcester
Affinivax
Location(s):
Cambridge
Alere
Location(s):
Waltham
Amgen
Location(s):
Cambridge, Woburn
Astellas
Location(s):
Cambridge, Marlborough
AstraZeneca
Location(s):
Waltham
Beckman Coulter
Location(s):
Danvers
Bristol-Myers Squibb
Location(s):
Cambridge, Devens, Waltham
Celgene
Location(s):
Cambridge
Charles River Laboratories
Location(s):
Shrewsburg, Wilmington, Woburn, Worcester
Disease Diagnostic Group
Location(s):
Cambridge
Eli Lilly and Company
Location(s):
Cambridge
EMD Serono
Location(s):
Billerica, Rockland
Emergent Biosolutions
Location(s):
Canton
Genocea Biosciences
Location(s):
Cambridge
GSK
Location(s):
Cambridge
Merck & Co
Location(s):
Boston
Microbiotix
Location(s):
Worcester
Nanbiosym
Location(s):
Cambridge
Novartis
Location(s):
Cambridge
Oxford Immunotec
Location(s):
Boston, Marlborough, Norwood
Pfizer
Location(s):
Andover, Cambridge
Quidel
Location(s):
Beverly
Quigen
Location(s):
Waltham, Mansfield
Sanofi
Location(s):
Allston, Cambridge, Framingham, Northborough, Waltham
Sarepta Therapeutics
Location(s):
Andover, Cambridge
Transgene
Location(s):
Cambridge

Massachusetts's top areas of global health R&D by USG funding

38.7%
HIV/AIDS
6.5%
Malaria
25.8%
Tuberculosis
12.3%
Diarrheal diseases
1.8%
Bacteria pneumonia & meningitis
10.1%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
Trachoma
4.7%
Other
Ebola/viral hemorrhagic fevers
Hepatitis C
Non-allocable
Salmonella infections

Global health R&D at work in Massachusetts

Researchers from Harvard Medical School, Partners In Health, and Boston Children’s Hospital have shown that a new commercially developed rapid test for Ebola, performed at the point of care, was as effective as a conventional laboratory-based method. The successful field trial is a potential gamechanger. A test that can accurately diagnose Ebola within minutes provides clinicians with crucial information for treating patients and containing outbreaks.

Footnotes